ENB Therapeutics is developing therapies to help the 50% of cancer patients who have resistance to common drugs. ENB is developing a line of products that can be paired with these otherwise ineffective treatments to stimulate the immune system and target and kill cancer cells, including those of melanoma and ovarian and pancreatic cancers.
The company’s first product, ENB-003, is a selective small molecule endothelin B receptor (ETBR) inhibitor that can aims to help reduce cancer growth and spread and prolong survival.
President/Co-Founder: Sumayah Jamal
Headquarters: New York City, NY
Year Founded: 2015
Year Avestria First Invested: 2022 (Fund II)
Looking for a job opportunity at ENB Therapeutics? Click here.
Recent Press:
Coherus announces collaboration to evaluate LOQTORZI® and ENB-003
12 women-led biotech companies that crushed it in 2023
ENB announces top-line Phase 1B study results
ENB Therapeutics announces completed enrollment for Phase 1 trial
The Checkpoint Inhibitor Refractory Cancer market should see continued growth
ENB Therapeutics is presenting at the 2023 BIO CEO & IO 360⁰ Conferences
ENB Therapeutics is presenting at the 2022 Summit for Cancer Immunotherapy
ENB Therapeutics announces Orphan Drug Designation for ENB-003
ENB Therapeutics demonstrated early efficacy in Phase I clinical trial of ENB-003
ENB Therapeutics announces clinical trial collaboration with Merck to evaluate ENB-003
ENB Therapeutics closes Series-A financing round
May 8, 2024: Coherus BioSciences, Inc., which markets LOQTORZI® (toripalimab-tpzi) - a PD-1 inhibitor - is collaborating with the Cancer Research Institute (CRI) and ENB Therapeutics. The three will work together on a platform study - called Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer or IPROC - to test LOQTORZI® in combination with ENB’s ENB-003 for the treatment of ovarian cancer. Long-term, this study will test the combination of the two therapies while, short-term, it expands the number of patients who can benefit from this innovative immunotherapy solution.
December 27, 2023: ENB Therapeutics made Biotech Metropolitan Women’s list of the 12 women-led biotech companies that “crushed it” in 2023. The article cited ENB’s positive results of its phase I clinical trial which used ENB-003 to treat refractory solid tumors and ovarian cancer and how ENB-003 enhances the efficacy of other drugs, like Merck’s KEYTRUDA®, in recurring or resistant cancer.
November 7, 2023: ENB presented the top-line results from its ENBOLDEN-101 trial, which investigated the safety and efficacy of ENB-003 in combination with Merck’s anti-PD-1 therapy: KEYTRUDA® for patients with platinum resistant/ refractory ovarian cancer (PROC). The results, first presented at the Society for Immunotherapy of Cancer 2023 meeting, found an objective response rate (ORR) and disease control rate (DCR) of 40% and 80% respectively, compared to a ~8% ORR and a ~22% DCR for a single agent anti-PD1 treatment. In other words, patients responded to the combination of ENB-003and KEYTRUDA® and it controlled their cancer more than a single anti-PD1 treatment, like KEYTRUDA® alone, has shown to do. 80% of the ENBOLDEN patients also had a shrinkage of target lesions overall.
July 18, 2023: ENB Therapeutics announced that it has completed enrollment for its international Phase 1 ENBOLDEN-101 trial, which will investigate the safety and efficacy of ENB-003 in combination with Merck’s anti-PD-1 therapy: KEYTRUDA® (also known as pembrolizumab). The completed enrollment follows the Phase 1/2a study, which was broken into two parts. The first was dose-escalation study to determine the recommended dosage; the second was a safety, tolerability and efficacy of ENB-003 in combination with pembrolizumab in cancers that do not respond to standard-of-care treatments, like specific types of ovarian cancer, pancreatic cancer, and melanoma. The results of the study will be presented at the Immuno-oncology Summit in early August.
February 8, 2023: According to new data, the market for checkpoint inhibitors for cancer treatment is supposed to grow steadily over the next ten years; going from its 2023 valuation of $38.69B to about $112.43B by 2033. This report also includes information about the market by type of cancer and about the major players in the space: a list that includes ENB Therapeutics.
February 6, 2023: ENB Therapeutics has been selected for an oral presentation at the 2023 BIO CEO and IO 360⁰ conferences. The BIO CEO is one of the largest conferences in the life science industry for investors while the Immuno-Oncology 360⁰ conference focuses on the latest in immuno-oncology specifically. Sumayah Jamal is presenting at both conferences: on February 6 for BIO CEO and on February 9 for IO 360⁰
November 4, 2022: ENB Therapeutics is presenting its poster at the 2022 Summit for Cancer Immunotherapy (Summit4CI 2022), The poster will cover ENB’s performance with KEYTRUDA® ( brand name: pembrolizumab) for advanced refractory solid tumors. The Phase 2 portion of this trial, combining the two treatments, is projected to start in the first quarter of 2023.
May 24, 2022: The FDA has granted Orphan Drug Designation to ENB’s lead product, ENB-003, for the treatment of pancreatic cancer. An Orphan Drug Designation helps stimulate investigational therapies through incentives such as tax credits for clinical costs, exemptions from certain FDA fees and even up to seven years of marketing exclusivity once the FDA approves the drug. This Orphan Drug Designation is the second one received by ENB-003, which was also granted Orphan Drug Designation for melanoma in 2016.
February 1, 2021: ENB Therapeutics has announced the successful completion of its third dosing cohort in a Phase I clinical trial. The trial is measuring dose escalation of ENB-003 in combination with pembrolizumab. The company has observed observed continued safety as well as early efficacy signals, including a partial response in a ovarian cancer patient who had a ~72% reduction in tumor burden and no disease progression at six months of therapy.
November 17, 2020: ENB Therapeutics' Investigational New Drug Application (IND) for its lead product, ENB-003, has been approved by the FDA. An IND is required for companies to start administering investigational drugs to human subjects. With this approval, ENB remains on schedule to start its clinical trial in late 2020 to evaluate the safety and efficacy of ENB-003 in combination with pembrolizumab, which helps treat melanoma and ovarian cancer among others.
February 4, 2019: ENB Therapeutics and Merck are partnering for a clinical trial to measure the efficacy, safety, and tolerability of ENB-003, ENB Therapeutics’ product, both as a monotherapy and in combination with Merck’s therapy, KEYTRUDA®. The study will enroll subjects who experienced previous drug treatment failure for their melanoma, ovarian or pancreatic cancer.
September 20, 2018: ENB Therapeutics has announced the closure of its Series A round of funding. The proceeds of the raise will be used to advance the company’s lead product - an investigational drug compound known as ENB-003 - through pre-clinical and early clinical development. Remiges Ventures led the round while New York State Development, BioAdvance, and Alexandria Ventures also participated.